Evommune
Manufacturing · California, United States · 25 Employees
View Company Info for Free
About
Headquarters
1841 Page Mill Rd Ste 100, Palo Alto, Californi...Phone Number
(650) 223-7745Website
www.evommune.comRevenue
$8.4 MillionIndustry
Most Recent Scoops
Highlights
$185M
Total Funding Amount
$115M
Most Recent Funding Amount
3
Number of Funding Rounds
Who is Evommune
Evommune Org Chart
Is Evommune your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Evommune is spiking on competitors!
Evommune, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Evommune has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Evommune recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Evommune
Check if Evommune has recently received funding, and reach out quickly before it becomes old news!
Click to see if Evommune had a recent Job posting/layoffs
Product Launch: Get notified when Evommune launches new products
Recommended Actions
Find VP level buyers at Evommune
Find 2 more new buyers
Compare Similar Companies to Evommune
Compare insights from companies similar to Evommune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Evommune
Evommune financials insights
Gather financial insights about Evommune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Evommune Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Evommune Tech Stack
A closer look at the technologies used by Evommune
Most Recent Scoops
Evommune News & Media
Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline ... - Pulse 2.0
Evommune - a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases - announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA Capital Management and Sectoral Asset Management, along with participation from new investors B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealthNew Investment in Series C Round of Evommune, Inc. | Company Announcement | Investegate
Investegate announcements from New Investment in Series C Round of Evommune, Inc.Evommune raises $115M to accelerate immune drug tests - BioPharma Dive
The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” regarding a future IPO, its CEO said.Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
– Financing co-led by RA Capital Management and Sectoral Asset Management – – Proceeds to support clinical development of lead program MRGPRX2 inhibitor, EVO756, as well as IL-18 targeted fusion protein program, EVO301 – – Multiple Phase 2 data readouts expected in 2025 and 2026 in...
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Evommune
Evommune, Inc. is a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases. The company is creating game-changing science with the goal of delivering therapies that address symptoms and halt progressive disease.... Read More